The future of drug design

RECEPTOR.AI provides an AI-powered drug discovery platform for pharma, biotech and academia that covers the whole drug discovery pipeline in a flexible and scalable manner

About us
Our mission

RECEPTOR.AI aims to develop next-generation membranotropic drugs to combat oncology and cardiovascular diseases.

We intend to design new superior drugs, which combines the best features of protein- and membrane-targeting compounds to create bifunctional drugs with superior properties.

Our vision

We dream about a world where new drugs are developed so fast, that new diseases have no chances to spread.

We envision radical minimization of drug testing on animals and humans with improvement of their safety and efficiency by combining advanced AI with novel organ-on-a-chip technologies.

Our team
Taras Voitsitskyi
Lead Bioinformatician,
AI Engineer
Medicinal Chemist
Ihor Koleiev
Zakhar Ostrovsky
Machine Learning
Volodymyr Vozniak
Machine Learning
Machine Learning
Roman Zhytar
Pavel Henitsoi
Data Engineer
Ivan Khropachov
Data Scientist
Business and Project Development Officer
Anastasia Balashova
Product Manager, Biotechnologist
Miroslav Ujazdowski
Scientific Advisor
Mikhail Bogdanov
PhD, Professor of Biochemistry and Molecular Biology.
30+ years of experience in experimental studies of lipid membranes and membrane proteins. An author of the charge-balance rule of membrane proteins topogenesis. An expert in "lipid mutants", selective lipid labeling, design and assessment of the membrane-targeting compounds.
Scientific Advisor
Christophe Ramseyer
PhD, Professor of Physics
20+ years of experience in the surface physics, biophysics, quantum chemistry and computational drug design. An expert in simulating interactions of theragnostic nanoparticles with the cell membranes, quantum simulations of the drugs, bridging molecular simulations with bio-medicine and pharmacology.
Chief Executive Officer,
Alan Nafiev
An experienced A.I leader, with previous start up experience in B2B environment, specialist in architecture design and business strategy. Alan assisted the company in securing Series A funding along with leading commercialisation of the technology in addition to a number of pilot roll outs of the software in the USA.
Chief Technical Officer,
Sergii Starosyla
PhD in Molecular Biology with 10+ years of experience in drug discovery and scientific software development. Medicinal chemist, expert in development of machine learning models, algorithms for pharmacophore modelling and molecular docking. Author of the number of patented anticancer and antimicrobic biologically active compounds.
Chief Scientific Officer
Semen Yesylevskyy
Dr. Semen Yesylevskyy, PhD, Dr.Sci. in biophisics. 15+ years of experience in molecular modeling, computational drug discovery and scientific software development. Author of unique techniques and algorithms in simulations of curved and asymmetric lipid membranes and assessment of drug-membrane interactions.
Roman Stratiichuk
R&D Manager,
Medicinal Chemist
Leonid Popryho
Lead AI Engineer
Book a demo
No Spam. Cancel Anytime.